Argentine hemorrhagic fever

(redirected from Argentine haemorrhagic fever)
Also found in: Dictionary, Thesaurus, Wikipedia.
Related to Argentine haemorrhagic fever: Machupo virus, viral hemorrhagic fever, Bolivian hemorrhagic fever, Bolivian hemorrhagic fever virus

Argentine hemorrhagic fever

an acute febrile viral illness caused by an arenavirus transmitted to humans by contact with or inhalation of aerosolized excreta of infected rodents. Initially, it is characterized by chills, fever, headache, myalgia, anorexia, nausea, vomiting, and a general feeling of malaise. As the disease progresses, the victim may develop a high fever, dehydration, hypotension, flushed skin, abnormally slow heartbeat, bleeding from the gums and internal tissues, hematuria, and hematemesis. There may be involvement of the central nervous system, shock, and pulmonary edema. There is no specific treatment for the disease other than hydration, rest, warmth, and adequate nutrition. Rarely, IV fluids and dialysis are necessary. Usually, the prognosis is complete recovery. See also Arenavirus, Bolivian hemorrhagic fever, Lassa fever.
A viral illness caused by the Junin arenavirus, named in 1953 after its city of isolation
Epidemiology Transmitted by contact with rodent urine; 23 outbreaks have been recorded in the maize-producing region of Argentina
Rodent vectors Akodon arenicola, Calomys laucha, C musculinus
Management Rehydration; high—15–45%—mortality may decrease to 1–4% with convalescent serum-specific Junin virus immune plasma

Argentine hemorrhagic fever

A viral illness caused by the Junin arenavirus Epidemiology Transmitted by contact with rodent urine; 23 outbreaks have been recorded, in the maize-producing region of Argentina Rodent vectors Akodon arenicola, Calomys laucha, C musculinus Clinical 1-2 wk incubation, followed by mucocutaneous hemorrhage, fever, anorexia, N&V, fluid loss and oliguria, hypotension, shock, severe myalgia, leukopenia, thrombocytopenia, transient hypocomplementemia Management Rehydration; high–15-45% mortality may ↓ to 1-4% with convalescent serum-
specific Junin virus immune plasma